Economic impact of managing invasive mold disease with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Spain-Reference-Cited by-同舟云学术

Economic impact of managing invasive mold disease with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Spain

Published:2024-03-18 Issue: Volume: Page:1-8
ISSN:1478-7210
Container-title:Expert Review of Anti-infective Therapy
language:en
Short-container-title:Expert Review of Anti-infective Therapy

Author:

Moya-Alarcón C.¹,Azanza J.R.²,Barberán J.³,Ferrer R.⁴,Kwon M.⁵,Moreno A.⁶,Rubio-Terrés C.⁷,Gálvez-Santisteban M.¹

Affiliation:

1. Medical Affairs Department, Pfizer SLU, Madrid, Spain

2. Department of Clinical Pharmacology, University of Navarra, Pamplona, Spain

3. Department of Intensive Medicine, Hospital HM Montepríncipe, Madrid, Spain

4. Department of Intensive Medicine, Hospital Universitari Vall d’Hebron, Barcelona, Spain

5. Department of Hematology, Hospital Gral. Univ. Gregorio Marañón, Institute of Health Research Gregorio Marañón, Madrid, Spain

6. Department of Pharmacy, Hospital Universitario Salamanca, Salamanca, Spain

7. Health Value SL, Madrid, Spain

Funder

Pfizer SLU

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14787210.2024.2327517

Reference42 articles.

1. The changing epidemiology of invasive fungal infections;Enoch DA;Methods Mol Biol,2017

2. Infección fúngica invasiva (IFI);Fernández B;Protoc Diagn Ter Pediatr,2023

3. Epidemiology and treatment approaches in management of invasive fungal infections

4. Patient Characteristics and Risk Factors in Invasive Mold Infections: Comparison from a Systematic Review and Database Analysis

5. WHO fungal priority pathogens list to guide research development and public health action. Geneva: World Health Organization; Licence: CC BY-NC-SA 3.0 IGO. 2022. [cited 2023 Aug 4]. Available from: https://www.who.int/publications/i/item/9789240060241